These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network. van de Donk NW; Palumbo A; Johnsen HE; Engelhardt M; Gay F; Gregersen H; Hajek R; Kleber M; Ludwig H; Morgan G; Musto P; Plesner T; Sezer O; Terpos E; Waage A; Zweegman S; Einsele H; Sonneveld P; Lokhorst HM; Haematologica; 2014 Jun; 99(6):984-96. PubMed ID: 24658815 [TBL] [Abstract][Full Text] [Related]
24. Emerging concepts in monoclonal gammopathy of undetermined significance. Freytes CO Bol Asoc Med P R; 2010; 102(4):43-6. PubMed ID: 21766546 [TBL] [Abstract][Full Text] [Related]
26. The clinical spectrum of IgM monoclonal gammopathy: A single center retrospective study of 377 patients. Cao XX; Meng Q; Mao YY; Su W; Zhen JF; Shen KN; Zhang CL; Huang XF; Duan MH; Zhang W; Zhu TN; Cai HC; Chen M; Zhou DB; Li J Leuk Res; 2016 Jul; 46():85-8. PubMed ID: 27232065 [TBL] [Abstract][Full Text] [Related]
27. UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS). Bird J; Behrens J; Westin J; Turesson I; Drayson M; Beetham R; D'Sa S; Soutar R; Waage A; Gulbrandsen N; Gregersen H; Low E; Br J Haematol; 2009 Oct; 147(1):22-42. PubMed ID: 19673884 [No Abstract] [Full Text] [Related]
28. Monoclonal gammopathies of undetermined significance. Kyle RA; Rajkumar SV Best Pract Res Clin Haematol; 2005; 18(4):689-707. PubMed ID: 16026745 [TBL] [Abstract][Full Text] [Related]
29. Polyneuropathy and monoclonal gammopathy of undetermined significance (MGUS); update of a clinical experience. Matà S; Torricelli S; Barilaro A; Grippo A; Forleo P; Del Mastio M; Sorbi S J Neurol Sci; 2021 Apr; 423():117335. PubMed ID: 33647732 [TBL] [Abstract][Full Text] [Related]
30. Peripheral neuropathy and monoclonal gammopathy of undetermined significance: a population-based study including 15,351 cases and 58,619 matched controls. Rögnvaldsson S; Steingrímsson V; Turesson I; Björkholm M; Landgren O; Yngvi Kristinsson S Haematologica; 2020 Nov; 105(11):2679-2681. PubMed ID: 33131261 [No Abstract] [Full Text] [Related]
33. Determining the clinical significance of monoclonal gammopathy of undetermined significance: a SEER-Medicare population analysis. Go RS; Gundrum JD; Neuner JM Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):177-186.e4. PubMed ID: 25445471 [TBL] [Abstract][Full Text] [Related]
34. Monoclonal gammopathies of clinical significance (MGCS): In pursuit of optimal treatment. Oganesyan A; Gregory A; Malard F; Ghahramanyan N; Mohty M; Kazandjian D; Mekinian A; Hakobyan Y Front Immunol; 2022; 13():1045002. PubMed ID: 36505449 [TBL] [Abstract][Full Text] [Related]